Nicholas L. Petrone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicholas L. Petrone has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Anna A. Griadunova
Innovative Genomics Institute, University of California, Berkeley, Berkeley, USA
1 shared publication- Brian Pallares
Department of Chemistry Colgate University Hamilton New York USA
1 shared publication - Camellia S. Huang
Department of Biology, The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, USA
1 shared publication - Daiyao Zhang
Department of Chemical Engineering, Stanford University, Stanford, USA
1 shared publication - Daniel S. Honeycutt
Department of Chemistry, University of Rhode Island, 140 Flagg Rd, Kingston, Rhode Island 02881, United States
1 shared publication - Fang Wang
Department of Chemistry, University of Rhode Island, 140 Flagg Rd, Kingston, Rhode Island 02881, United States
1 shared publication
Latest Publications
- Open Access
- 20 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Leveraging platinum-protein interactions to overcome chemoresistance
A common mechanism by which cancer cells acquire resistance to chemotherapeutics is through the overexpression of efflux pumps, enabling the removal of cytotoxic agents, such as anthracycline drugs. However, platinum anticancer agents that crosslink DNA and interact with proteins are poor efflux pump substrates. Here, we design dual warhead drug conjugates by tethering a platinum pharmacophore to the doxorubicin backbone. These drug conjugates retain the anticancer activity of anthracyclines and exhibit the ability to both circumvent drug efflux and delay the acquisition of drug resistance. In vivo experiments demonstrate that such drug conjugates extend survival in a preclinical organoid-based model of metastatic colon cancer in mice. Mechanistic studies indicate that these drug conjugates overcome resistance through covalent platinum-protein interactions, leading to significantly improved drug retention and alteration of subcellular drug distribution. This application of platinum offers many opportunities to confront issues related to chemoresistance and alternative pathways for augmenting conventional chemotherapeutics.
- 20 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-10
Open AccessLeveraging platinum-protein interactions to overcome chemoresistance
A common mechanism by which cancer cells acquire resistance to chemotherapeutics is through the overexpression of efflux pumps, enabling the removal of cytotoxic agents, such as anthracycline drugs. However, platinum anticancer agents that crosslink DNA and interact with proteins are poor efflux pump substrates. Here, we design dual warhead drug conjugates by tethering a platinum pharmacophore to the doxorubicin backbone. These drug conjugates retain the anticancer activity of anthracyclines and exhibit the ability to both circumvent drug efflux and delay the acquisition of drug resistance. In vivo experiments demonstrate that such drug conjugates extend survival in a preclinical organoid-based model of metastatic colon cancer in mice. Mechanistic studies indicate that these drug conjugates overcome resistance through covalent platinum-protein interactions, leading to significantly improved drug retention and alteration of subcellular drug distribution. This application of platinum offers many opportunities to confront issues related to chemoresistance and alternative pathways for augmenting conventional chemotherapeutics.